APA (7th ed.) Citation

Roncolato, F. T., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., . . . Friedlander, M. (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 148(1), 36. https://doi.org/10.1016/j.ygyno.2017.10.019

Chicago Style (17th ed.) Citation

Roncolato, Felicia T., et al. "Validation of the Modified Glasgow Prognostic Score (mGPS) in Recurrent Ovarian Cancer (ROC) – Analysis of Patients Enrolled in the GCIG Symptom Benefit Study (SBS)." Gynecologic Oncology 148, no. 1 (2018): 36. https://doi.org/10.1016/j.ygyno.2017.10.019.

MLA (9th ed.) Citation

Roncolato, Felicia T., et al. "Validation of the Modified Glasgow Prognostic Score (mGPS) in Recurrent Ovarian Cancer (ROC) – Analysis of Patients Enrolled in the GCIG Symptom Benefit Study (SBS)." Gynecologic Oncology, vol. 148, no. 1, 2018, p. 36, https://doi.org/10.1016/j.ygyno.2017.10.019.